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Background: To facilitate the discussion on the increasing number of total hip replacements (THR) and their
effectiveness, we apply a joint evaluation of hospital case costs and health outcomes at the patient level to enable
comparative effectiveness research (CER) based on the preoperative health state.
Methods: In 2012, 292 patients from a German orthopedic hospital participated in health state evaluation before
and 6 months after THR, where health-related quality of life (HRQoL) and disease specific pain and dysfunction were
analyzed using EQ-5D and WOMAC scores. Costs were measured with a patient-based DRG costing scheme in a
prospective observation of a cohort. Costs per quality-adjusted life year (QALY) were calculated based on the
preoperative WOMAC score, as preoperative health states were found to be the best predictors of QALY gains in
multivariate linear regressions.
Results: Mean inpatient costs of THR were 6,310 Euros for primary replacement and 7,730 Euros for inpatient
lifetime costs including revisions. QALYs gained using the U.K. population preference-weighted index were 5.95.
Lifetime costs per QALY were 1,300 Euros.
Conclusions: The WOMAC score and the EQ-5D score before operation were the most important predictors of
QALY gains. The poorer the WOMAC score or the EQ-5D score before operation, the higher the patient benefit.
Costs per QALY were far below common thresholds in all preoperative utility score groups and with all underlying
calculation methodologies.
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Because of scarce resources in health care systems and a
concurrent increasing number of total hip replacements
(THR) worldwide, cost-effectiveness and quality perform-
ance measures for THR are becoming more important [1].
With 295 THR per 100,000 inhabitants, Germany currently
has the highest THR rate among European Union countries
[2]. At over 210,000 operations, THR was among the top* Correspondence: matthias.vogl@helmholtz-muenchen.de
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unless otherwise stated.10 surgeries performed in Germany in 2011 [3]. With an
aging society, these numbers – and especially the number
of revision THR – will increase further. Future supply, de-
velopment, and innovation in THR will depend more and
more on its cost-effectiveness for certain patient groups [4].
Some National Health Service (NHS) trusts in the UK
already prioritize patient groups based on patient-reported
outcome measures (PROMs) to facilitate efficient and ef-
fective THR treatment [5,6]. The intense discussion on the
necessity for and the benefit of the increasing number of
THRs can be facilitated by this recent empirical evidence
on the average cost-effectiveness of THR in Germany,
which has not been analyzed to date. Thus, we apply a joint
evaluation of hospital costs and health outcomes at the
patient level to enable comparative effectiveness researchd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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medical and economic decision support in health care sys-
tems with scarce resources.
Currently, there are only separate analyses on the im-
pact of preoperative characteristics on length of stay [7],
Health-related Quality of Life (HRQoL) [8-17], and single
THR cost studies [18,19]. Thus, the existing literature in-
forms only on the overall costs and general resource use
of THR patients [20,21]. Because of the high cost and
health outcome differences in an international comparison
of THR, a patient group specific cost-effectiveness analysis
is necessary [19,22]. Thus, we calculate quality-adjusted
life years (QALYs) for several preoperative WOMAC
states. QALYs report the number of years gained in per-
fect health by measuring the difference in HRQoL before
and after THR. For reasons of comparability and country
specificity, we use three different concepts of cost-
effectiveness analyses from patient-reported health states:
(1) a QALY calculation based on the UK population
preference-weighted index to enable comparison with
other studies; (2) a QALY-like calculation based on
the German population experience-weighted index (EB-
QALY) to introduce the perspective of the general
German population; and (3) a visual analog scale adjusted
life year calculation (VAS-AL) to use the gold standard
of health outcome measures – the VAS – in cost-
effectiveness analyses. With an activity-based allocation of
costs calculated for each study patient, we calculate the
cost utility of THR for each patient.
QALYs are used increasingly by policy supporting insti-
tutions such as the National Institute for Health and Care
Excellence (NICE) to facilitate decision making [23,24].
With a CER based on the impact of preoperative patient
characteristics on QALYs, we support prioritization and
payment by results approaches in health policy and mod-
eling approaches in research. Management interventions
to provide cost-effective THR are supported by detailed
costing related to preoperative patient characteristics.
Thus, the aim of the study is to find preoperative patient
characteristics that predict the cost-effectiveness of THR
and quantify its impact on cost-effectiveness to support




From January to June 2012, 393 patients were eligible to
participate, 387 THR patients participated in the baseline
health state evaluation and 321 (82%) patients participated
in the follow-up. For 292 patients (74%) we received full
HRQoL information including all WOMAC and EQ-5D
health measures and attributable, patient-based costing
measures. Except for lack of patient consent, we had
no exclusion criteria. The study was performed at anorthopedic hospital in Munich (Hospital Barmherzige
Brüder München, university teaching hospital) and had
approval from the ethics committee of Klinikum rechts
der Isar, Technical University Munich. All patients
followed a similar clinical pathway, which is independ-
ent of preoperative patient characteristics, to fulfill the
prerequisite of the prognostic study design for patient-
group specific information on costs per QALY [25]. For
most patients osteoarthritis was the major diagnosis
(95.5%); some had osteonecrosis, mechanical complica-
tions, or infections that led to THR as the major diagno-
sis. For 21 patients we had some missing data in
covariates. Diagnostic tests showed that we can afford
loosing those cases for regression analyses. As imput-
ation could induce another bias in the analysis, we kept
the reduced dataset for regression and worked with the
full dataset in cost- and effectiveness analyses where a
comprehensive set of covariates is not necessary.
Study design
The innovation in the study design is a detailed acquisi-
tion and combination of costs and HRQoL data at the
patient level. While we measure costs with a standard-
ized, patient-based DRG costing scheme [26], effective-
ness is measured with a generic HRQoL instrument on
five health dimensions (EQ-5D) [27] before (baseline)
and 6 month after THR (follow-up) to enable change
score models that are related to case-based costs and
preoperative patient characteristics. In this single center,
prospective observation of a cohort, we define a set of
preoperative patient characteristics with an impact on
HRQoL or costs in prior clinical studies [8-17] and shed
light on THR cost-effectiveness for patients with differ-
ent preoperative characteristics.
To calculate life expectancy, we used the life expect-
ancy of each THR patient based on age and gender from
the life tables of the federal statistical office [28] and
multiplied them by the EQ-5D change scores to calcu-
late QALYs, assuming that the change score remains
constant during each patient’s individual life expectancy.
Based on literature recommendations, we discounted
QALYs and costs of potential revision by 3.5% [29]. On
account of very low differences in HRQoL comparing
primary and revision THR [30,31], and presumed simi-
larity in the literature [5], we did not distinguish be-
tween primary and revision THR concerning HRQoL.
Based on literature, we assigned a THR revision rate of
7.5% for the first 10 years and 1.5% for each following
year [5,32,33].
We calculate the average cost-effectiveness ratio
(ACER) for several THR groups compared with no inter-
vention. In the medical literature, the ACER and the in-
cremental cost-effectiveness ratio (ICER) are sometimes
used interchangeably with each other, especially when
Vogl et al. BMC Health Services Research 2014, 14:342 Page 3 of 12
http://www.biomedcentral.com/1472-6963/14/342the alternative to a procedure is only no intervention
[21]. In familiar interventions such as THR, where the
alternative is usually no intervention, empirical studies
have shown that the ICER is not preferable to the ACER
for medical decision making [34]. Thus, all cost-
effectiveness ratios in this paper refer to ACER.Measuring instruments
Clinical practice guidance mentions reduced HRQoL as a
limitation related to osteoarthritis [35]. The EQ-5D is a
generic HRQoL instrument, which generates an index value
based on a formula with respect to the preferences and
experiences of a country’s population out of the five dimen-
sions of mobility, self-care, usual activity, pain/discomfort,
and anxiety/depression [27]. A 5-digit code made up of
these five domains (each with 3 possible values: no prob-
lems, some problems, severe problems) allows 243 health
states, which are evaluated based on three different meth-
odologies to allow for comparability with U.K. and U.S.
studies and concurrent country specificity [29]. Thereby the
best health state is 1,1,1,1,1 (no problems in each dimen-
sion) and the worst health state is 3,3,3,3,3 (severe problems
in each dimension). The U.K. population preference-
weighted index uses a value for each 5-digit code that is
based on the time trade-off (TTO) preferences of the
general U.K. population [36]. The German population
experience-weighted index uses the VAS results from the
general German population to allocate a value to each 5-
digit state [27]. Additionally, the overall health state is mea-
sured using the VAS, which retrieves the overall health state
on a 0–100 scale in the study population. The German
experience-weighted index and the VAS do not fully qualify
for QALY calculation as they are not based on TTO and do
not include health states worse than death. Thus, they do
not conform to the common QALY definitions and are
therefore called experience-based QALY (EB-QALY), when
based on the German experience-weighted index, and VAS
adjusted life years (VAS-AL), when based on the VAS scale.
All EQ-5D calculations allow a comprehensive evaluation
of the actual value of an intervention for the patient: it is a
comparative effectiveness measure for HRQoL that is rec-
ognized as reliable, valid, and responsive in the literature
[37,38]. The WOMAC score is a disease specific score that
measures pain and dysfunction of the hip. To measure
hip-specific outcome from a patients’ perspective, we
use the WOMAC with its three subscales on pain
(5 sub-questions), stiffness (2 sub-questions), mobility
(17 sub-questions), and an overall score based on the
three subscales. To make the overall score comparable
to EQ-5D results, we transformed WOMAC results to a
0–100 scale where 0 is the poorest measure and 100 is
the best measure. Each WOMAC question has a Likert
scale from 0 to 10. The WOMAC shows the bestpsychometric characteristics in THR specific question-
naires [39-41].
The costing scheme of the Institute for the Hospital Re-
muneration System (InEK) was introduced to calculate re-
imbursement rates for DRGs in a transparent and efficient
way [42]. In 2011, 263 hospitals participated in the calcu-
lation [26]. It provides a detailed, patient-based cost ac-
counting scheme, which is used by hospitals to participate
in the reporting process that their reimbursement is based
on. We use the InEK costing scheme to calculate case
costs and analyze the impact of preoperative characteris-
tics on resource utilization and case costs. Costs and
resource use in the scheme are split into several cost-
categories (physicians, nursing, medical/technical staff,
drugs, implants, other material, medical- and nonmedical
infrastructure) and cost-centers (ward, operating room,
anesthesia, intensive care, diagnostics/therapy, radiology,
and laboratories). The cost breakdown allows a compari-
son with other THR costing studies in the U.S., the U.K.,
and other European countries [18,19,22].Statistical analysis
Patient characteristics with potential impact on cost-
effectiveness are included in three subdomains: (1) socio-
demographic factors, including age, gender, marital status,
housing situation, kind of discharge, and kind of insur-
ance; (2) medical factors, including BMI, major diagnosis,
all frequent secondary diagnoses, the number of second-
ary diagnoses, ASA classification, Charlson Comorbidity
Index, metabolic syndrome, all major procedures and fre-
quent side procedures (e.g., use of cement), number of op-
erations and procedures, number of operations on
affected joint before hospital stay, major hip distortion,
and preoperative hemoglobin value; (3) HRQoL, pain,
function, and mobility before THR, measured by EQ-5D,
WOMAC, and Harris Hip Score.
Spearman’s correlation was used to examine the bivariate
relation of independent variables to costs and QALYs. Co-
variates with a relation (p < 0.05) were included in a multi-
variate linear regression analysis (OLS). OLS was used for
cost and QALY analyses, as both were normal distributed.
A backward selection method was used to determine the
final set of covariates in the OLS on costs and QALYs. Co-
variates were considered relevant for p < 0.05. We provide
descriptive statistics for cost and QALY gains separated by
preoperative WOMAC groups, the most predictive pre-
operative patient characteristic according to OLS analysis.
For patient differentiation we used the WOMAC as a stan-
dardized and specific, patient-based reporting measure. As
WOMAC and EQ-5D are correlated we could not elimin-
ate the “regression to the mean” issue [43], a general limita-
tion of cohort studies when analyzing subgroups. Data
analysis was performed using SPSS 21 software.
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Some 58% of the study population was female, the aver-
age age was 68 years, and most patients had an ASA
score of 1 or 2 and a Charlson Comorbidity Index of 0
or 1 (Table 1). Most patients received cementless pri-
mary THR with osteoarthrosis of the hip as the major
diagnosis. Compared to the population in a large Euro-
pean Study that includes also a representative German
sample [44], our population is slightly younger, has less
secondary diagnoses (lower average Charlson Comorbid-
ity Index), and patients have shorter length of stay and
lower costs. 89% of patients were in the major DRGs for
THR (I47A and I47B). Table 1 shows all the control vari-
ables and their correlation with costs and QALYs. Corre-
lations were detected, e.g., for acute anemia, diabetes,
depression, sleep disorder, major hip distortion, number
of secondary diagnoses, number of operation and pro-
cedure codes, open reposition fracture, operations at
joint before procedure, housing situation, health insur-
ance, ASA score, and Charlson Comorbidity Index.
OLS regressions showed the relationship of sev-
eral preoperative characteristics to inpatient costs and
QALYs. The impact of WOMAC and EQ-5D was pro-
vided separately to avoid multi-collinearity. Both pre-
operative measures are correlated. For the grouping of
QALY gains we used the WOMAC as it is most accepted
among orthopedics and mostly used in day-to-day rou-
tines. Both preoperative scores have similar impact on
QALY gains but low impact on inpatient costs, as pa-
tients were treated very similar. Generally, there was low
variance in inpatient THR costs but the number of oper-
ation and procedure codes, the number of secondary
diagnoses, health insurance, and revision THR had an
impact on costs (Table 1). Mean costs of THR were €
6,310 (95% confidence interval € 6,160 - €6,472) with
the highest costs for ward and operating room in the
cost-center view and the highest costs for physicians,
implants, and infrastructure in the cost category view
(Table 2). Revision THR increases inpatient costs by
18%. Average life expectancy of the study population is
17.57 years. Studies show that the probability of revision
is 7.5% for the first 10 years after primary THR and 1.5%
for each year thereafter [5,33], resulting in average life-
time inpatient costs of € 7,730 for THR. The grouping
by preoperative WOMAC score shows a trend that
healthier patients cost less (Table 3).
Mean EQ-5D utility score change was 0.33 with the
U.K. preference based value set as the underlying utility
scores (preoperative 0.51; postoperative 0.84). With the
German experience-based value set, EQ-5D utility score
change was 0.22 (preoperative 0.54; postoperative 0.76).
The VAS score change was 18.45 (preoperative 59.76;
postoperative 78.22). Change scores were not affected by
either gender or age. Bivariate analysis showed highcorrelation of preoperative WOMAC scores with QALYs
gained. In a multivariate OLS analysis, the preoperative
EQ-5D and WOMAC scores had the highest impact on
the effectiveness of THR and therefore QALYs (Table 4).
Thus, we provided QALY calculation for preoperative
WOMAC groups. Among all preoperative characteris-
tics, the preoperative WOMAC score suits best for pay-
ment by results approaches, modeling approaches, and
management interventions to provide cost-effective
THR.
QALYs gained using the U.K. preference based value
set were 5.95. Lifetime costs per QALY were € 1,300.
Using the German experience-based value set as the
underlying set for EQ-5D utility scores showed an EB-
QALY gain of 4.05 with € 1,908 per EB-QALY. The VAS
showed a VAS-AL gain of 3.43 and costs of € 2,256 per
VAS-AL. VAS results were divided by 100 to calculate
VAS-AL and to be comparable with the U.K. QALYs
and the German EB-QALYs. All three value sets for
QALY and QALY-like calculation showed a large in-
crease in QALY gains with a decrease in preoperative
WOMAC scores, indicating that patients with poor
WOMAC scores benefit most from THR (Table 3).
QALY gains are higher when patients are less healthy.
The separation of study participants into age groups
showed that even the oldest age group, which naturally
gains the fewest QALYs, had low QALY costs (Table 5).
The economic perspective of QALYs is further corre-
lated with direct medical pain and dysfunction scores,
e.g., the Harris Hip Score (Figure 1), showing that phys-
ician based questionnaires can also be used for a health
economics perspective.
Discussion
Multivariate regression analyses gave an overview of the
actual drivers of cost-effectiveness in THR: costs were
mainly increased by special procedures, such as exci-
sion/resection of the diseased bone and open reposition
of fracture, or by revision (Table 4). Preoperative patient
characteristics had no important and systematic impact
on THR costs. On the effect side, some preoperative
characteristics can impact health outcome significantly.
Depression, reflux, and major hip distortion significantly
reduce QALY gains (Table 4). A higher ASA score and
revision compared with primary THR also significantly
reduce QALY gains. Increased age and high EQ-5D
scores reduce QALY gains the most. We have average
THR costs of € 6,310 with a 95% confidence interval of
€ 6,160 - €6,472, with a trend that healthier patients cost
less (Table 3). In countries with similar purchasing pow-
ers to those in the U.S. or Europe – and where health in-
surance is available – costs are not the limiting factor
when contrasting them with QALY gains in cost-
effectiveness analyses. Patient characteristics that affect
Table 1 Impact of relevant preoperative patient characteristics
Significant Spearman’s rank correlation: relation of secondary diagnoses, operations/procedures, and




Secondary diagnoses, at least 10 times
D62 - Acute anemia* 26 8.9 1
E03 - Hypothyroidism 48 16.5 1
E11 - Diabetes* 23 7.9 1
E66 - Obesity 18 6.2 1
E78 - Lipidemia 30 10.3 1
E79 - Purine/pyrimidine metabolism 13 4.5 1
E86 - Hypovolemia* 13 4.5 1
E87 - Dysfunction of water/electrolyte balance* 18 6.2 1
F32 - Depression^ 12 4.1 1
G47 - Sleep disorder* 10 3.4 1
I10 - Arterial hypertonicity 160 55.0 1
I25 - Ischemic heart disease 16 5.5 1
I48 - Atrial fibrillation 12 4.1 1
J45 - Asthma^ 12 4.1 1
M16 - Coxarthrosis 281 96.6 1
N18/N39 - renal failure and related diseases 17 5.8 1
T81 - Other complications* 11 3.8 1
Z86 - Personal anamnesis other diseases 11 3.8 1
Z88 - Drug allergy 15 5.2 1
Z91 - Risk factors in personal anamnesis 15 5.2 1
Z92 - Care of personal anamnesis 43 14.8 1
Z95 - Cardiac/vascular implants 24 8.2 1
Z96 - Other functional implants 48 16.5 1
n.n. - Cardiopathy 28 9.6 0
n.n. - COPD 12 4.1 0
n.n. - Hypercholesterolemia 44 15.1 0
n.n. - Myocardial infarction/stent 20 6.9 0
n.n. - Reflux^ 18 6.2 0
n.n. - Major hip distortion*^ 20 7.0 0
n.n. - deep venous thrombosis (DVT) 12 4.1 0
Number of secondary diagnoses* 3.4 (3.0) 1
Operations and procedures, at least 5 times
5-782 - Excision/resection of diseased bone* 5 1.7 2
5-791 - Open reposition of fracture* 6 2.1 2
5-820 - Primary endoprosthesis (no revision) 281 96.7 2
5-821 - Revision* 10 3.4 2
5-829 - Other arthroplasty* 10 3.4 2
5-986 - Minimally invasive technique 271 93.4 2
8-919 - Acute pain relief 5 1.7 2
8-930/1 - Monitoring* 30 10.3 2
Number of operation and procedure codes* 2.4 (1.2) 2
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Table 1 Impact of relevant preoperative patient characteristics (Continued)
Other
Age^ 68 (10.2) 1
Gender male 121 41.6 1





Mechanical complications/infections 9 3.1
Operations at joint before procedure*^ 1
0 265 91.1
1 19 6.5








With partner 146 50.7
With family 61 21.2
Discharge home (other, inpatient rehabilitation) 56 19.2 3
Health insurance compulsory (other, private)* 149 51.2 1
Already THR 61 20.9 0
Preoperative hemoglobin* 14.0 (1.2) 0




3 or higher 24 8.2




3 or higher 7 2.4
Metabolic syndrome* 8 2.7 0
Cement or hybrid (other, cementless)^ 34 11.9 7
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WOMAC (or EQ-5D) score, which qualifies these pa-
rameters to be included in shared decision making with
the patient for professionals. This makes a QALY thresh-
old, but not a cost per QALY threshold, important for
health policy related to THR.As the WOMAC score and EQ-5D scores predict the
patient benefit and QALY gains best, they should be
used in patient reported outcome measures (PROMs) in
the future. PROMs are becoming important as a quality
measure from the patient’s perspective and for pay for
performance approaches. Because of the differentiation
Table 2 Inpatient cost calculation














Ward 438 731 0 64 1 0 53 3 196 765 2,251
Intensive care 7 18 0 3 0 0 4 0 1 6 40
Operating room 434 0 306 6 0 1,709 165 64 162 229 3,075
Anesthesia 242 0 153 22 0 0 49 0 29 69 563
Cardiac diagnostics 1 0 0 0 0 0 0 9 0 0 10
Endoscopic diagnostics 1 0 1 0 0 0 1 0 1 1 4
Radiology 22 0 26 4 0 0 8 4 6 22 91
Laboratories 2 0 36 6 11 0 32 8 4 12 111
Further diagnostics/therapy 2 0 113 0 0 0 3 0 4 44 166
All cost-centers 1,148 749 635 104 12 1,709 314 87 403 1,148 6,310



















Table 3 QALY calculation – separated by preoperative WOMAC score































0-20 14 47.50 21.68 74.86 16.49 27.36 23.26 16.48 7.95 7,043 1,813 8,421 1,778 4.10 3.25 3.38 2,055 2,313
21-40 75 50.09 22.85 71.99 22.07 21.89 27.63 16.71 8.68 6,698 1,860 8,100 2,304 4.46 6.93 2.73 1,816 2,737
41-60 110 59.19 17.86 78.10 19.95 18.91 22.82 17.16 7.9 6,198 1,036 7,582 1,843 3.25 4.88 2.41 2,332 2,892
61-80 77 68.09 16.48 83.31 12.44 15.22 20.35 18.58 7.16 6,034 978 7,487 1,419 2.79 3.99 2.05 2,684 3,310
81-100 16 79.69 16.23 86.63 10.79 6.94 17.55 20.39 7.61 5,948 617 7,568 1,118 2.27 4.73 1.00 3,337 6,757
Sum 292 59.76 20.72 78.22 18.78 18.45 23.55 17.57 7.92 6,310 1,341 7,730 1,854 3.43 5.23 2.39 2,256 2,964































0-20 14 0.04 0.12 0.81 0.17 0.77 0.16 16.48 7.95 7,043 1,813 8,421 1,778 12.40 6.17 9.50 679 823
21-40 75 0.30 0.31 0.76 0.25 0.46 0.33 16.71 8.68 6,698 1,860 8,100 2,304 8.20 8.78 5.76 987 1,300
41-60 110 0.54 0.25 0.86 0.15 0.31 0.28 17.16 7.90 6,198 1,036 7,582 1,843 5.85 6.77 3.98 1,295 1,751
61-80 77 0.70 0.17 0.88 0.16 0.18 0.24 18.58 7.16 6,034 978 7,487 1,419 3.28 4.64 2.40 2,281 2,829
81-100 16 0.80 0.06 0.94 0.10 0.14 0.14 20.39 7.61 5,948 617 7,568 1,118 3.16 2.81 2.03 2,393 3,329
Sum 292 0.51 0.30 0.84 0.19 0.33 0.31 17.57 7.92 6,310 1,341 7,730 1,854 5.95 7.08 4.25 1,300 1,669


































0-20 14 0.34 0.06 0.72 0.17 0.39 0.15 16.48 7.95 7,043 1,813 8,421 1,778 6.49 4.60 4.76 1,297 1,643
21-40 75 0.44 0.13 0.71 0.18 0.27 0.18 16.71 8.68 6,698 1,860 8,100 2,304 4.71 5.09 3.39 1,721 2,207
41-60 110 0.53 0.12 0.77 0.14 0.24 0.17 17.16 7.90 6,198 1,036 7,582 1,843 4.39 4.17 3.04 1,726 2,292
61-80 77 0.65 0.12 0.80 0.12 0.15 0.17 18.58 7.16 6,034 978 7,487 1,419 2.79 3.62 2.02 2,685 3,368
81-100 16 0.73 0.08 0.86 0.06 0.12 0.11 20.39 7.61 5,948 617 7,568 1,118 2.59 2.20 1.75 2,920 3,856



















Table 4 Multivariate regression analysis on costs and QALY gains
Dependent variable: QALYs (U.K. preference-weighted) Coefficient Beta SE p-value
Constant 43.810 3.130 .000
Preoperative WOMAC sum -.153 -.396 .018 .000
ICD F32 - Depression −3.266 -.096 1.597 .042
G47 - Sleep disorder −4.843 -.109 2.327 .038
Reflux −2.645 -.094 1.337 .049
Major hip distortion −3.770 -.140 1.290 .004
OPS 8-930/1 - Monitoring 2.709 .107 1.334 .043
Age -.331 -.466 .034 .000
n = 271 Adj. R2 = .418
Dependent variable: QALYs (U.K. preference-weighted) Coefficient Beta SE p-value
Constant 42.268 2.240 .000
Preoperative EQ-5D utility score (U.K. preference-weighted) −15.316 -.658 .805 .000
ICD F32 - Depression −2.673 -.078 1.176 .024
Reflux −1.829 -.065 .970 .060
Major hip distortion −3.205 -.119 .946 .001
Age -.318 -.447 .026 .000
ASA 2 (compared to ASA 1) -.846 -.060 .498 .090
n = 271 Adj. R2 = .685
Dependent variable: inpatient costs Coefficient Beta SE p-value
Constant 6,338 845 .000
Preoperative EQ-5D utility score (U.K. preference-weighted) −426 -.109 177 .017
ICD J45 - Asthma −508 -.085 274 .065
Number of secondary diagnoses 103 .242 25 .000
OPS 5–782 - Excision/resection of diseased bone 1,435 .147 468 .002
OPS 5–791 - Open reposition of fracture 1,699 .194 401 .000
OPS 5–821 - Revision 1,811 .185 462 .000
OPS 8-930/1 - Monitoring −686 -.162 233 .004
Number of operations and procedures 461 .409 63 .000
Age −11 -.098 5 .038
BMI 25 .105 10 .018
Preoperative hemoglobin −83 -.081 47 .079
n = 271 Adj. R2 = .502
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in their decisions on THR, they can support health pol-
icy with prioritization decisions based on QALY thresh-
olds and net benefit analysis based on willingness to pay,
and they can support hospital management through a
differentiated analysis of costs (Table 2) and the impact
of patient and care selection on costs and QALY gains
(Table 4). Age is the second driver of QALY gains. Simi-
lar to other studies on THR cost-effectiveness [33,45],
age has a low impact on the EQ-5D change score itself
(younger people expect slightly higher health benefits
from THR), but it affects the life expectancy component
of QALY calculation. Still, all WOMAC and age groupsbenefit from THR and have low costs per QALY
(Tables 3 and 5). THR is a cost-effective intervention for
all analyzed WOMAC and age groups when applying
the common cost per QALY thresholds from NICE, the
World Health Organization, and other institutions that
provide national guidance and advice on improving
health care [21,46].
The advantages of ACER analysis in this study, accord-
ing to Bang and Zhao [47], are that (1) clinical and
economical characteristics of THR are analyzed inde-
pendently of an alternative or no intervention; (2) ACER
results are thus intuitive for research and policy; (3) re-
sults are more robust compared with ICER; and (4) a
Table 5 QALY gains by age
Underlying value set Age group
≤59 60-69 70-79 ≥80
QALYs
VAS-AL based 6.398 3.280 1.697 0.990
UK QALY based 10.967 6.122 4.341 2.531
German EB-QALY based 7.565 4.098 2.583 1.506
QALYs discounted 3.5%
VAS-AL based 3.922 2.357 1.953 0.860
UK QALY based 6.723 4.399 3.105 2.199
German EB-QALY based 4.637 2.944 2.269 1.308
Cost/QALY in €
VAS-AL based 1.927 3.085 3.771 9.391
UK QALY based 1.124 1.653 2.372 3.672
German EB-QALY based 1.630 2.469 3.246 6.171
Cost/QALY in €; discounted 3.5%
VAS-AL based 1.738 2.857 3.569 9.071
UK QALY based 1.014 1.530 2.245 3.547
German EB-QALY based 1.470 2.286 3.072 5.961
Figure 1 QALYs by preoperative WOMAC and harris hip score.
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cision making. Further advantages of the study were,
first, the detailed bottom-up costing approach for each
patient that was based on the actual resource use of each
single patient. The costing method is verifiable and com-
parable, as each case had to pass plausibility checks by
the InEK to be part of the study [26]. The separation of
costs into components (Table 2) enables comparative
and transparent costing analyses. Second, the prospect-
ive study design allowed the attribution of actual patient
costs to health outcome scores to calculate cost-utility
(QALY) for each patient. Thus, it is the first German
study to report cost-effectiveness or cost-utility values
for THR. The calculation of EB-QALYs and VAS-ALs
besides QALYs has the advantage that – although they
do not conform to the rigorous QALY definition – EB-
QALYs and VAS-ALs are closer to the actual experi-
ences of THR patients than QALYs but still have the
advantages of QALY calculation.
Limitations of the study include: (1) inability to re-
trieve health states after a potential revision or for longer
follow-up periods. Thus, we extrapolated the EQ-5D
utility score change of the 6-month follow-up for QALY
calculation. In this way, we assume that the change score
remains constant during each patient’s individual life ex-
pectancy. This assumption is rather conservative, as the
literature shows that HRQoL for THR patients is slightly
higher a year after operation compared with at the 6-
month follow-up [48]. However, this method is widely
accepted and used in the literature [5,48]; (2) the EQ-5D
change scores of revision patients differed slightly fromprimary THR change scores (−0.02) in our study. Similar
to other studies, we assumed that revisions keep the
change in HRQoL at the 6-month follow-up level [5]; (3)
18% of patients were lost in the follow-up. They did not
differ significantly in preoperative socio-demographic and
medical factors. However, similar to other THR studies
[5], they had slightly lower mean preoperative EQ-5D
scores (−0.01 with the experience-weighted index), which
indicates a conservative estimate and a slightly higher EQ-
5D change score if these patients were included in the
study. As we have a monocentric study, representativeness
of patients might not be given; (4) we used the WOMAC
as a preoperative patient characteristic for health state and
dysfunction for categorizing QALY results. However, as
WOMAC and EQ-5D utility scores are correlated, we
could not eliminate the general limitation of regression to-
ward the mean, potentially leading to inaccurate results
when comparing preoperative patient groups on costs and
QALYs. The use of WOMAC in standardized PROMs is
more likely anyway, as disease specific instruments such
as the Oxford Hip/Knee Score are already used for
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http://www.biomedcentral.com/1472-6963/14/342prioritization in the U.K. [6]; and (5) the inpatient cost ac-
counting scheme used had some minor limitations
[26,42]. The full-cost approach did not include capital
costs, and although German DRG costing has a high ac-
curacy, it is not the gold standard in every calculation
step.
In comparison with other cost-effectiveness literature,
our results range as follows: average QALY gains were
similar to many U.K. and U.S. studies [5,33,49,50]. How-
ever, especially in methodologically similar UK studies,
average preoperative health scores are lower compared
with this study, allowing a higher increase in scores [5].
Here, we suppose an operation at an earlier coxarthrosis
stage in Germany than in the U.K. Costs per QALY were
mostly similar [5,33] or lower [20,21,49] compared with
methodologically comparable studies.
In a future perspective, studies should take a closer
look at the actual comparative group of THR patients.
In this study, we identified the preoperative WOMAC
score as a good predictor of QALY gains. However, simi-
lar to most other studies, we compared with a virtual
group of patients with no intervention and assumed that
their health state remained at the level of THR patients
before operation. This might under- or overestimate the
real benefit of THR compared with no intervention or
compared with pain relief instead of THR [51]. Thus,
WOMAC and health outcomes should be analyzed for
patients who decided against THR compared with
THR patients. A separation into preoperative WOMAC
groups, as in this study, can then show which patients
benefit most and for which patients cost-utility is highest
with conservative therapy. A matching of pre- and post-
operative EQ-5D values with population normative
values can quantify the utility of total hip replacement
for preoperative health state groups. Finally, a compari-
son of patient reported outcome measures and related
micro-costing with other countries allows a detailed
comparison of cost-effectiveness and possibly conclu-
sions on weakness in the health care system.
Conclusions
The WOMAC score and the EQ-5D score before oper-
ation were the most important predictors of QALY
gains. The poorer the WOMAC score or the EQ-5D
score before operation, the higher the patient benefit.
Although differences in QALY gains and costs per QALY
were high between the three methodologies of cost-
utility analysis, they were far below common thresholds
in all preoperative utility score groups and with all
underlying calculation methodologies [21,46]. CER re-
sults might be used in pay for performance approaches
for an efficient and effective health care system [52].
Health outcome and micro-costing measures in combin-
ation are useful performance measures to comparehospitals on a patient-level basis. CER results support
patients in a shared decision making situation before
THR based on a personalized risk assessment approach.
They support prioritization decisions in health policy
concerning preoperative health states. And they support
hospital management through differentiated costing and
health outcome measures on a patient basis.
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